Kardiologie up2date 2009; 5(3): 206-212
DOI: 10.1055/s-0029-1215272
Hotline – Koronare Herzerkrankung und Atherosklerose

© Georg Thieme Verlag KG Stuttgart · New York

Die JUPITER-Studie: Antworten und Fragen?

Felix  Post, Thomas  Münzel
Further Information

Publication History

Publication Date:
15 October 2009 (online)


Over the last years the indication for a therapy with statins has been expanded. The recently published JUPITER-Trial (Jusfication for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) was conducted to test, if indication for statin therapy can be expanded even further. The study compared rosuvastatin 20 mg daily vs placebo in apparently healthy people with levels of low-density lipoprotein cholesterol (LDL) lower than 130 mg/dL but showed an elevation (≥ 2 mg/L) of high-sensitivity C-reactive protein (hs-CRP). Rosuvastatin treatment lowered LDL-C levels by 50 % and hs-CRP levels by 37 %, accompanied by a 44% relative risk reduction in the composite end point of unstable angina, revascularization, and confirmed death from cardiovascular causes. The number-needed-to treat was 95 patients over a 2 year period to prevent one event. We would like to discuss this study with current data on statin therapy and focus on possible implications of the study results.


Dr. med. Felix Post

Universitätsmedizin Mainz
II. Medizinische Klinik für Kardiologie, Angiologie und Intensivmedizin

55131 Mainz

Email: [email protected]